Recite me link

Q1. How many patients were treated in April 2021 (or latest available month) by the dermatology department with the following drugs:
a. Baricitinib (Olumiant)
b. Dupilumab (Dupixent)
c. Ixekizumab (Taltz)
d. Risankizumab (Skyrizi)
e. Guselkumab (Tremfya)
f. Secukinumab (Cosentyx)
Q2. How many patients were treated in April 2021 (or latest available month) by the rheumatology department with the following drugs:
a. Baricitinib (Olumiant)
b. Filgotinib (Jyseleca)
c. Ixekizumab (Taltz)
d. Secukinumab (Cosentyx)
e. Upadacitinib (Rinvoq)

Download response Treatment of dermatological and rheumatological conditions. 210621